Avalo Therapeutics, Inc. current report, 02 March 2017

Business Context and Reporting Period

This Form 8-K was filed by Cerecor Inc. on March 2, 2017, reporting an event that occurred on February 24, 2017. The filing addresses a regulatory compliance issue regarding the company's listing status on the Nasdaq Stock Market.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on stock price compliance rather than financial performance metrics.

Material Changes

The material change reported is a deficiency in compliance with Nasdaq Listing Rule 5550(a)(2). The company's common stock closing bid price remained below $1.00 for the last 30 consecutive business days prior to the notice date.

Outlook, Risks, and Management Commentary

  • Compliance Period: The company has been granted a 180-calendar day period, ending August 23, 2017, to regain compliance.
  • Regaining Compliance: To satisfy the rule, the closing bid price must be at least $1.00 for a minimum of ten consecutive business days at any time during the compliance period.
  • Delisting Risk: If compliance is not achieved by the deadline, the company will receive written notification that its listed securities (common stock, Class A warrants, and Class B warrants) are subject to delisting.
  • Management Action: The company is evaluating various courses of action to regain compliance but stated there can be no assurance of success.

Investor Verification Checklist

  • Verify the current closing bid price of Cerecor Inc. common stock to assess progress toward the $1.00 threshold.
  • Monitor for any subsequent filings regarding a reverse stock split or other capital structure changes intended to address the price deficiency.
  • Confirm whether the company has submitted an appeal if the August 23, 2017, deadline is missed.
  • Review the trading status of Class A and Class B warrants, as they are also subject to the potential delisting determination.